Cargando…
Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
BACKGROUND: Ritlecitinib is an oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family inhibitor undergoing parallel clinical development for alopecia areata, vitiligo, ulcerative colitis, Crohn’s disease, and rheumatoid arthritis. OBJECTIVE: As studies read out simultaneous...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684409/ https://www.ncbi.nlm.nih.gov/pubmed/37917289 http://dx.doi.org/10.1007/s40262-023-01318-3 |